Precision Fermentation as an Alternative to Animal Protein, a Review

Abstract

The global food production system faces several challenges, including significant environmental impacts due to traditional agricultural practices. The rising demands of consumers for food products that are safe, healthy, and have animal welfare standards have led to an increased interest in alternative proteins and the development of the cellular agriculture field. Within this innovative field, precision fermentation has emerged as a promising technological solution to produce proteins with reduced ecological footprints. This review provides a summary of the environmental impacts related to the current global food production, and explores how precision fermentation can contribute to address these issues. Additionally, we report on the main animal-derived proteins produced by precision fermentation, with a particular focus on those used in the food and nutraceutical industries. The general principles of precision fermentation will be explained, including strain and bioprocess optimization. Examples of efficient recombinant protein production by bacteria and yeasts, such as milk proteins, egg-white proteins, structural and flavoring proteins, will also be addressed, along with case examples of companies producing these recombinant proteins at a commercial scale. Through these examples, we explore how precision fermentation supports sustainable food production and holds the potential for significant innovations in the sector.

1. Introduction

The global food production system is facing increasing challenges, driven both by increasingly noticeable climate change and by population growth estimated to exceed 9.7 billion individuals by 2050 [1]. Addressing these challenges requires a delicate balance: increasing food production to meet the needs of a growing population while at the same time mitigating the environmental pressure imposed by current agricultural practices. Agriculture contributes significantly to global greenhouse gas (GHG) emissions, representing at least 26% of the total, with livestock production alone responsible for half of this production [2,3]. Consequently, the imperative to seek more sustainable protein sources has never been more urgent, especially to ensure future food security [4,5].

In parallel, recent years have seen a pronounced shift in consumer food preferences towards healthier food choices, along with a growing awareness of the ethical considerations and animal welfare associated with animal products [6]. This evolution in consumer attitudes, coupled with environmental issues associated with animal products, has catalyzed interest and investment in an innovative field—cellular agriculture. Coined around 2015, cellular agriculture encompasses the production of products traditionally derived from animals through alternative means, using bioreactors instead of conventional livestock farming [7,8,9]. This new technology is designed to revolutionize the food industry, and might be part of the solutions to ensure food security in the future.

Within this scenario, precision fermentation has emerged as an aspect of cellular agriculture. Recognized as an integral part of the fourth industrial revolution in the food industry [10], the concept of precision fermentation has recently been proposed [11]. It represents a broad concept that encompasses all fermentation processes meticulously optimized through specially designed host microorganisms, which function as “cell factories” with the aim of generating high-value functional products [12]. Growing consumer demand for sustainable, cruelty-free products, alongside increasing government support, has driven the expansion of the alternative protein market [6]. Although precision fermentation has been used for several decades to produce various compounds [11], especially enzymes, within the context of cellular agriculture, precision fermentation has emerged as a solution to obtaining animal proteins without the use of animals. Unlike the analogous proteins provided by the “plant-based” industry, the proteins produced by precision fermentation are bioidentical to the traditional ones of animal origin, having the same nutritional value and sensory properties. This offers an opportunity to respond to the growing demand for protein, while also addressing environmental concerns, food safety, and animal welfare issues. However, scaling up precision fermentation from lab to commercial production poses challenges, requiring innovative engineering and optimized processes [7,8,9]. Regulations are also falling behind new technology developments, necessitating comprehensive guidelines and updates to address safety, efficacy, and GMO-related ethical concerns [8].

Despite these obstacles, precision fermentation shows significant promise. In food, it offers sustainable alternatives to traditional animal agriculture, reducing environmental impact. It allows, for example, the production of new infant milk formulas, sweets and nutritious drinks, and flavorings for plant-based meats. In healthcare, it enables personalized medicine and production of rare, complex molecules, driving drug development innovation. As research advances, precision fermentation’s transformative potential across industries is undeniable, promising a more sustainable future. This review provides a summary of the environmental impacts related to the current global food production and explores how precision fermentation can contribute to address or at least mitigate these issues. Additionally, we report on the main animal-derived proteins produced by precision fermentation, with a particular focus on those used in the food and nutraceutical industry.

2. The Environmental Impacts of Animal-Based Production

There is now ample evidence that achieving climate change targets also depends on addressing the environmental consequences of food production, particularly those of animal origin [13,14]. Furthermore, for the first time in 28 editions, the United Nations Convention on Climate Change or Conference of the Parties (COP) has put the transformation of food systems on the global climate agenda with more than 150 countries signing the Cop28 UAE Declaration on Sustainable Agriculture, Resilient Food Systems, and Climate Action [15]. This action highlights global awareness of the urgent need to reform current dietary practices, recognizing them as fundamental to tackling climate change [13,14,15,16].

The livestock supply chain, responsible for a significant portion of global GHG emissions—estimated at between 11% and 20%—represents a primary focus of attention [17,18,19]. The impact, however, goes beyond GHG emissions, including profound changes to the Earth system. Remarkably, 83% of the world’s agricultural land is used for meat, aquaculture, and egg and dairy production, contributing just 18% of the calories and 37% of the proteins consumed globally [17]. Analysis of environmental implications, supported by the FAO, reveals that agriculture is the main agent of global deforestation, being responsible for around 80% of it [20]. A worrying example is found in the Brazilian Amazon, where the weakening of enforcement against deforestation resulted in a spike in deforested areas in 2019 and 2020, reaching 1.11 million hectares annually. This increase in deforestation, often illegal, is attributed to the expansion of cattle ranching and soybean cultivation, changing the Amazon’s function from a carbon sink to a carbon emitting source. This intensifies concerns related to climate change and global environmental impacts [21,22].

The pronounced loss of biodiversity is also an issue of concern, with the production of animal-based foods being one of the main causes of the global reduction of natural habitats and associated with the extinction of numerous species in the modern era [23,24]. Furthermore, livestock activity has exceeded planetary freshwater use limits in several countries, posing additional threats to biodiversity [25,26,27]. The intensive consumption of water for agricultural irrigation, which represents around 70% of global freshwater extraction and 90% of global human consumption, highlights the substantial impact of livestock farming on water resources [28].

The need for action against the climate crisis becomes even more urgent given the current effects of rising global temperatures. To have any hope of meeting the central objective of the Paris Agreement, which is to limit global warming to 2 °C or less, our carbon emissions must be significantly reduced, including those from agriculture. Analysis shows that even if fossil fuel emissions were eliminated immediately, emissions from the global food system alone would make it impossible to limit warming to 1.5 °C and difficult to even reach the 2 °C target [15,29]. Therefore, major changes to the way food is produced are needed if we are to meet the goals of the Paris Agreement. Worrying projections for the remaining carbon budget needed to keep temperature rise below 1.5 °C indicate a significant probability that we have already passed that threshold, suggesting that the chances of limiting warming without resorting to excess or high-risk geoengineering (and bioengineering) may have been compromised [30]. Additionally, some analyses include data that point to accelerated glacial melt, with glaciers losing 31% more snow and ice annually than they did 15 years ago [31]. This trend reinforces the seriousness of the current climate situation and the imperative need for effective measures to mitigate climate change.

In addition to the climate issue, another environmental issue is waste pollution. The process of raising animals for food generates substantial waste, including manure and offal, pesticides, veterinary products and their containers, plastics from silage production, as well as slurries, and other organic wastes, which can pollute water bodies and soil. Such waste can often constitute the majority of waste produced by the agricultural sector. Although manure and slurry are often used as fertilizers, the sheer volume produced can exceed the soil’s needs, so they can become more of a problem to be eliminated than a valuable resource to be utilized. Poor management of these materials can result in environmental damage, such as water contamination and increased biochemical oxygen demand [32]. All of these data highlight the need to address the environmental impacts of food production of animal origin, emphasizing the need for collaborative efforts to transition to more sustainable and environmentally friendly production practices.

3. Precision Fermentation as Part of the Solution

Multiple studies have already shown that current production and consumption patterns in the agricultural sector are unsustainable to support a growing population and, at the same time, achieve a climate-sustainable future [33]. Fortunately, precision fermentation presents itself as a potential solution to several problems in the current global production system. In terms of environmental impact, precision fermentation has been shown to be superior to animal products, with some foodstuffs requiring approximately 90% less land use and 96% less water [10,34,35]. Furthermore, life cycle assessment studies indicate that precision fermentation can result in significantly lower GHG emissions, 97% less in some cases, compared to many forms of traditional production, especially those derived from animal sources [34,35,36]. This reduction is associated with decreased emissions of methane, a gas that retains more than 100 times the heat of CO₂ on a mass basis, and that is mainly emitted by animal production, through enteric fermentation and manure management [37]. Recent analyses indicate that more than 80% of future warming due to food consumption will come from high-methane food groups [33]. This is because methane emissions are relatively short-lived and the approximately 30% of current warming attributed to methane comes almost entirely from recent emissions [35]. Thus, reducing methane emissions can quickly benefit the climate. In this context, the substitution of animal-derived products by the rapid deployment of precision fermentation technology could play an important role in halting and even reversing climate change by reducing the likelihood of extreme weather and climate events [35].

In this context, the rapid deployment of precision fermentation technology could play an important role in halting and even reversing climate change by reducing the likelihood of extreme weather and climate events [35]. On the other hand, the global food production system depends on stable environmental conditions, such as adequate sunlight, favorable temperatures and regular precipitation. These elements can be significantly altered by both natural and anthropogenic factors. Furthermore, our food chain is also subject to other serious threats, including crop-affecting pathogens, herbicide-resistant weeds, devastating pest outbreaks, the emergence of superbugs, and the alarming decline of pollinators [38]. These risks, whether isolated or combined, highlight the vulnerability of our food system. The fragility of this system has become even more apparent with supply chain disruptions caused by the COVID-19 pandemic, which has further emphasized the vulnerability of contemporary food systems [39]. In this sense, precision fermentation allows for a much more resilient production process [40]. This is because this approach allows production in a closed and fully controlled environment, so that systems are not directly susceptible to adverse weather conditions. In addition, precision fermentation also eliminates the need for animal slaughter, addressing ethical concerns related to animal welfare and reducing the risk of zoonotic diseases and antibiotic resistance, which are significant public health issues associated with intensive animal farming [41,42]. By producing clean and safe proteins without the need for animals, precision fermentation enhances both ethical standards and public health outcomes.

Microorganisms can be grown and multiplied quickly using cheap substrates (often by-products of other processes), leading to faster and more efficient production [43,44] and, different from animal products, precision fermentation produces minimal waste, as microorganisms can be engineered to maximize yield and efficiency. Furthermore, the byproducts of microbial fermentation are often valuable inputs for other industrial processes, contributing to a circular economy and reducing overall environmental pollution [45,46,47]. Although the production of animal proteins through precision fermentation for the food industry is a relatively new area and initially associated with higher costs, continuous improvement efforts promise to overcome these challenges. Since the 1980s, precision fermentation has been a proven technology commercially used for the production of human insulin, growth hormones, enzymes such as rennet (chymosin), and various other biological products. Many vitamins and supplements are produced almost exclusively through this technique. The cost of precision fermentation has significantly decreased over the years, from USD 1 million/kg in 2000 to about USD 100/kg currently, with a forecast to drop below USD 10/kg by 2030 [48]. This suggests that precision fermentation is poised to surpass livestock farming in terms of cost, capacity, speed, and volume of food production, resulting in a significant improvement in the efficiency of industrial food production. Investing in research and development to expand precision fermentation technologies will reduce production costs, making them more accessible and profitable for a broader population and creating new markets and job opportunities. Fostering partnerships between governments, the private sector, and research institutions is essential to promote the adoption and rapid development of precision fermentation and other emerging alternative protein technologies, such as plant-based proteins, mycoproteins, and cultured meats. These innovations are critical in ensuring high-quality food production as we transition to low-carbon emission food practices. Embracing these technologies will be indispensable for ensuring a more sustainable future for the next generations.

4. The Precision Fermentation Process

The precision fermentation process is carried out in several steps, as summarized in Figure 1. This process begins with the careful selection of a suitable host platform for gene expression. Microorganisms classified as generally recognized as safe (GRAS) are preferably adopted in industrial contexts. In this scenario, bacteria, yeast [49] and filamentous fungi [50] emerge as the main vehicles for microbial engineering. Within the bacterial group, Escherichia coli stands out for its low production cost and high concentrations of recombinant proteins produced [51,52]. However, it faces limitations with those proteins that require specific post-translational modifications (PTMs) [53]. E. coli does not favor the formation of disulfide bonds in the cytoplasm [54], a challenging characteristic for the expression of eukaryotic proteins, since most of them depend on these bridges for their proper structure [55]. Furthermore, the ability of E. coli to glycosylate proteins is exceptionally rare, a process fundamental to the structure and function of some proteins [56,57]. Therefore, bacteria are preferentially used for the expression of proteins devoid of PTMs or in circumstances where such modifications are not crucial for protein functionality [58].

On the other hand, yeasts such as Komagataella phaffii (formerly Pichia pastoris), support a wide range of PTMs, including disulfide bonds, phosphorylation, N-acetylation, and glycosylation [59,60]. Its efficiency, cost-effectiveness, and high productivity make this yeast a popular choice for the production of eukaryotic proteins [50]. K. phaffii is also notable for its ability to achieve high cell densities and, consequently, increased protein yield, in addition to not secreting many proteins inherent to it, which simplifies the downstream process [60,61,62,63,64]. A nice example of how to optimize a microorganism for the production of recombinant proteins is the development of a license-free (OPENPichia) K. phaffii strain [65]. Practically all studies using K. phaffii yeasts for the production of recombinant proteins use strain NRRL Y-11430 (or industrial derivative strains from it), a strain that is not available without restrictions on its use, requiring a material transfer agreement (MTA) precluding third-party distribution and use for product manufacturing, and royalty payments are imposed on products manufactured with it. Claes and collaborators performed comparative genome sequencing analysis of four types of strains (including NRRL Y-11430) and identified strain NCYC 2543 (note that the NCYC collection provides liberal distribution and commercial use licenses) as genomically almost identical to NRRL Y-11430. Both strains had practically the same growth rates, and expressed several recombinant proteins (under the control of two different promoters) with nearly the same yields. However, the transformation efficiency of strain NCYC 2543 was significantly lower than that of strain NRRL Y-11430, which was shown to be the consequence of a premature stop codon (present in this last strain) in the HOC1 gene encoding an α-1,6-mannosyltransferase involved in the synthesis of cell-wall mannan. When the mutation was introduced into strain NCYC 2543, the obtained NCYC 2543 hoc1^tr strain (OPENPichia) with a truncated HOC1 protein had a transformation efficiency 1.5–3-fold higher than strain NRRL Y-11430, and did not alter (in some cases indeed improved) the production of recombinant proteins, even when tested in bioreactors [65,66]. Finally, since expression kits used in commercial applications require licensing from the kit provider, the authors also provide a genetic toolkit and cloning framework free to the community based on golden gate cloning [67] with different and exchangeable promoters, signal peptides, epitope tags, terminators, selection markers, insertion sites, etc.

Other yeasts, such as Saccharomyces cerevisiae, Yarrowia lipolytica, and Kluyveromyces marxianus, are also employed as models for the industrial production of enzymes and food ingredients [47,49]. However, the respiro-fermentative metabolism of S. cerevisiae, the so-called Crabtree effect, results in lower energy efficiency and biomass yield, which can impact yields of proteins to be produced using this cell factory. This Crabtree effect is a consequence of high rates of sugar uptake and increased glycolytic fluxes, and due to a limited respiratory capacity results in overflow metabolism and ethanol production [68]. In order to increase respiration and cell biomass by this yeast, two main approaches were developed: reducing or restricting sugar uptake to prevent carbon overflow to ethanol [69,70,71], or interfering in the transcriptional control of metabolism [72,73,74,75,76]. In line with the importance of gene regulation for the establishment of the Crabtree effect is a report showing that overexpression of a single transcriptional regulator of the zinc cluster family (encoded by the CRA1 gene) transforms the typical Crabtree-negative yeast K. phaffii into a Crabtree-positive yeast that produces ethanol under aerobic conditions [77]. In any case, the use of respiratory yeasts increases recombinant protein yield even under conditions of (aerobic) high sugar concentrations [78,79].

Similarly, filamentous fungi such as Aspergillus and Trichoderma, categorized as GRAS, demonstrate remarkable competence in protein folding processes and PTMs. These species stand out for their ease of induction and their ability to degrade lignocellulose, a cheap, abundant, and widely distributed substrate [80]. Due to their effectiveness in producing extracellular enzymes, these fungi are considered favorable hosts for the secretion of recombinant proteins [81,82]. However, the ability of these fungi to produce proteases, which can compromise the integrity of the desired product, represents a limitation. Additionally, cell lysis, a common event during fermentation, can result in the release of intracellular proteases, negatively affecting the yield of recombinant proteins. Another aspect to be considered is the discrepancy in glycosylation mechanisms between fungi and mammalian cells, which may limit the applicability of these hosts in the expression of certain proteins [81,82].

The second phase of this process (Figure 1) is the expression of the gene of interest in the selected strain. Initially, a decision is made between stable or transient expression strategies, each with distinct advantages in terms of duration and levels of protein production. Then follows codon optimization, a crucial step to align the gene’s genetic code with the preferences of the host organism, ensuring efficient translation. Next, an expression cassette is carefully designed, which includes appropriate promoter and terminator sequences to effectively regulate gene expression. Another important decision is determining whether the protein will be secreted by the host cell or retained internally. Next steps involve the metabolic engineering of the microorganism through classical homologous recombination techniques or using advanced genome editing tools such as CRISPR-CAS9. This approach is integrated into a biological engineering cycle (Figure 1) known as design—build—test—learn (DBTL), aiming to maximize protein production. This iterative cycle allows for testing of multiple genetic designs [83,84,85,86].

DBTL cycles (Figure 2) begin with the design phase (D), which focuses on defining the desired functionalities and characteristics of the microorganism and protein of interest. This step includes digital modeling of genetic elements, circuits, metabolic and regulatory pathways, and even complete genomes. The build (B) phase deals with the physical construction of the genetic parts. The test (T) phase is dedicated to evaluating these designs in living cells or a chassis at different scales, which may include detailed omics analysis (for example, genomics, transcriptomics, and proteomics). Finally, the learn (L) phase uses modeling and computational learning to improve the design based on data obtained in the T phase [87]. These steps are widely used when wanting to improve microbial strains, their metabolic pathways, product yields, and scaling up for industrial production of ingredients with high added value [88,89,90].

Recombinant protein production may often impose a metabolic burden due to high demand for precursor molecules, consumption of redox and energy cofactors, and overload of misfolded and unfolded proteins in the endoplasmic reticulum (ER) lumen, causing imbalances in the cellular metabolism. These demands can create bottlenecks, limiting efficiency of the protein production. Metabolic engineering should address these issues by boosting precursor availability, maintaining redox and energy balance, or co-expressing helper genes involved in the unfolded protein response (UPR) pathway, leading to the development of a more robust strain [44,91]. In addition, the target protein yields can be increased by adjusting secretion sequences and promoters, the number of gene copies, using helper proteins such as chaperones, and exploring changes in membrane lipid composition, as demonstrated by different academic groups and private companies [87,92,93,94,95].

After the strain is meticulously adjusted to achieve the desired yield of the recombinant product, the transition stage from laboratory-scale production to large-scale production begins, involving minute adjustments of fermentative parameters (essential nutrients, substrates, and fermentation conditions). This phase ensures efficient transfer to larger volumes, preserving product quality and yield and optimizing production efficiency [90,96,97]. The final phase, also called the downstream process, involves recovery and purification to isolate the recombinant product from other by-products. For non-secreted proteins, this involves cell lysis to extract the proteins of interest.

The incorporation of artificial intelligence (AI) and machine learning with deep neural networks into the DBTL process represents a significant advancement. This technology allows scientists to analyze complex biological processes with much greater speed and precision than ever before. It is being used to improve and accelerate projects by combining computational methods with practical experimentation, thereby increasing the efficiency and effectiveness of protein expression and speeding up the process of microorganism engineering [85,97]. With the help of AI and robotics, we will be able to formulate millions of potential versions of new products and food ingredients and simultaneously analyze and test them through high-throughput screening. This will ensure the best combination of nutrition, taste, aroma, and mouthfeel. We have now reached the point where scientists can design and synthesize almost any known or unknown molecules. As technologies advance, costs will significantly decrease, allowing these innovations to be achieved much more cheaply than ever before [58].

5. Animal Proteins Produced by Precision Fermentation

5.1. Milk Proteins

The main function of breast milk is to ensure the survival, growth, and development of the newborn, providing not only essential nutrients, but also non-nutritive elements that fight infections and contribute to the maturation of organs [98]. Although approximately 96% of children begin breastfeeding shortly after birth, only 48% are exclusively breastfed during the first six months of life. This phenomenon occurs due to a series of reasons, ranging from biological limitations, such as difficulties in breastfeeding, to socioeconomic challenges, such as balancing returning to work and breastfeeding [99]. Although infant formulas have been developed to reproduce the composition and functionalities of breast milk, they cannot offer all the benefits inherent to human milk [100]. Most of these formulas are based on cow’s milk, which has a different composition than human milk. For example, while caseins predominate in bovine milk, human milk is rich in whey proteins such as lactoferrin, α-lactalbumin, and immunoglobulins (Table 1), which strengthen the immune system. Breastfed babies have a lower incidence of respiratory infections and a reduced risk of obesity and long-term metabolic disorders compared to those fed infant formulas based on cow’s milk [101,102]. Given this, there is significant interest in the development of a more advanced infant formula that contains real human milk proteins, stimulating research into the recombinant expression of these proteins.

Milk is a complex fluid, containing hundreds of molecular species. Among its main constituents are water, lipids, the sugar lactose, and proteins, forming a diverse nutritional matrix. Milk proteins, recognized for being a complete source of essential and non-essential amino acids, are of high quality and have a high absorption rate. These characteristics make them ideal for protein supplementation, especially for athletes, due to their nutritional benefits [103,104,105,106]. In milk, proteins can be divided into two main groups: caseins (CN) and whey proteins (Table 1), in addition to significant differences in protein composition between human and bovine milk. Whey, a byproduct of cheese making, contains proteins with extensive applications in diverse industries, ranging from bakery and dairy products to food toppings, beverages, and sports supplements. There is a variety of caseins in bovine milk, with αs1-casein (αs1-CN) being the most abundant. Human milk, for example, has lower amounts of caseins and does not contain αs2-casein (αs2-CN) and β-lactoglobulin, which are present in bovine milk, illustrating the protein diversity between species.

Table 1. Main proteins present in human and bovine milk during different stages of lactation (data adapted from [107,108]).

		Content (g/L)
Milk Proteins		Human	Bovine
Caseins	αs1-CN	0.09–0.87	8.0–10.7
	αs2-CN	–	2.8–3.4
	β-CN	0.28–2.47	8.6–9.3
	κ-CN	0.36–1.12	2.3–3.3
Whey proteins	α-lactalbumin	0.86–3.67	1.2–1.3
	β-lactoglobulin	–	3.2
	lactoferrin	0.93–3.0	0.1–0.5
	lysozyme	0.07–0.51	Trace
	IgA	0.49–1.85	0.1–0.2

Table 1. Main proteins present in human and bovine milk during different stages of lactation (data adapted from [107,108]).

		Content (g/L)
Milk Proteins		Human	Bovine
Caseins	αs1-CN	0.09–0.87	8.0–10.7
	αs2-CN	–	2.8–3.4
	β-CN	0.28–2.47	8.6–9.3
	κ-CN	0.36–1.12	2.3–3.3
Whey proteins	α-lactalbumin	0.86–3.67	1.2–1.3
	β-lactoglobulin	–	3.2
	lactoferrin	0.93–3.0	0.1–0.5
	lysozyme	0.07–0.51	Trace
	IgA	0.49–1.85	0.1–0.2

In addition to their role in nutrition, providing amino acids, milk proteins perform diverse biological functions. Caseins, for example, have the ability to bind metal ions, facilitating the absorption of essential nutrients, and are precursors of bioactive peptides that regulate important physiological functions [109]. The α-lactalbumin is essential for the biosynthesis of lactose, and is also an important source of essential amino acids for infant nutrition, including tryptophan, lysine, branched-chain amino acids, and sulfur-containing amino acids, all vital for child nutrition. This whey protein has about 6% tryptophan, a precursor of serotonin, related to the treatment of cognitive decline induced by chronic stress [101,110]. β-Lactoglobulin, in turn, has functions such as cholesterol reduction and antioxidant activity, but is also a potential allergen for babies [111,112]. Milk also contains proteins that modulate the immune system and offer a natural defense against microorganisms. Lactoferrin, for example, is a glycoprotein with several beneficial properties, found in high concentrations in human milk, especially colostrum. It performs crucial functions for neural development and protection against pathogens in newborns, in addition to having immunomodulatory, anti-inflammatory, antioxidant, and anti-cancer properties, among many others, highlighting its important role in maintaining human health [113]. Recent studies also point to the therapeutic potential of lactoferrin in the treatment of neurodegenerative diseases related to aging and emotional disorders linked to stress [114,115]. Due to the widespread use of milk proteins in the food and nutrition industry, the production of these proteins by precision fermentation has emerged as an area of great interest [116,117,118,119]. This movement illustrates a global effort to reconcile human nutritional needs with environmental sustainability, paving the way for innovations that can offer sustainable alternatives to the consumption of milk and its derivatives of animal origin.

Caseins are recognized for their significant importance both in the context of sports supplements and as fundamental elements in cheese production. There are four main types of caseins found in bovine milk (Table 1), which associate to form higher order protein structures, called casein micelles. These structures are composed of thousands of casein molecules and calcium salts, organized in calcium phosphate nanoagglomerates [120]. The integrity of these micelles is guaranteed internally by a network of caseins and calcium phosphate, while external stability is guaranteed by a layer of k-casein. During the cheese-making process, the removal of this outer layer leads to the destabilization of the micelles, thus facilitating the formation of a protein network [120,121,122,123]. Caseins have also been the focus of attention in precision fermentation, as they are the main components of cheese, and because of their melting capacity, are especially valued in this context. However, for the development of this type of product of non-animal origin, it is essential to reproduce the correct post-translational modifications to enable the adequate formation of micelles [123].

Although there are several old manuscripts describing the cloning and expression of αs1-CN and β-CN (bovine and human) in E. coli and S. cerevisiae, unfortunately there are no data regarding the amount of protein produced. For the bovine β-CN, the best production of an intracellular glycosylated form was attained with K. phaffii (

Table 2. Examples of successful production of recombinant animal proteins by microorganisms.

Proteins		Source	Host	Production (g/L)	Reference
Casein	β-CN	Bovine	K. phaffii	0.245	[124]
	MP-κ-CN	Human	S. cerevisiae	2.5	[125]
Whey proteins	α-lactalbumin	Human	K. phaffii	0.056	[126]
	β-lactoglobulin	Bovine	K. phaffii	1.0	[127]
		Porcine	K. phaffii	0.200	[128]
		Bovine	T. reesei	1.0	[129]
	lactoferrin	Human	Aspergillus awamori	2.0	[130]
		Porcine	K. phaffii	0.760	[131]
		Human	K. phaffii	1.2	[132]
		Human	glycoengineered K. phaffii	0.100	[133]
		Bovine	K. phaffii	3.5	[134]
Egg white	ovalbumin	Quail	K. phaffii	5.45	[135]
	ovotransferrin	Chicken	K. phaffii	0.100	[136]
	lysozyme	Chicken	K. phaffii	0.400	[137]
	avidin	Chicken	K. phaffii	0.330	[138]
Structural proteins	unhydroxylated collagen II	Human *	E. coli	10.8	[139]
	“gelatin-mimetic” hydroxylated collagen I	Human *	K. phaffii	3.4	[140]
	collagen (I, III)-like **	Human *	K. phaffii	2.33	[141]
	collagen I **	Human *	E.coli	1.88	[142]
	unhydroxylated collagen III	Human *	K. phaffii	4.68	[143]
	collagen III **	Human *	K. phaffii	1.05	[144]
	elastin-like	synthetic	K. phaffii	0.150–0.700	[145]
Flavoring proteins	hemoglobin ***	Human	E. coli	11.92	[146]
	myoglobin	Porcine	K. phaffii	0.247	[147]
	myoglobin	Porcine	K. phaffii	0.285	[148]
	leghemoglobin	Soy	K. phaffii	3.5	[149]
	leghemoglobin	Soy	K. marxianus	7.27	[150]
Other proteins	serum albumin ***	Human	E. coli	0.100	[151]
	serum albumin	Human	S. cerevisiae	0.200	[152]
	serum albumin ****	Human	S. cerevisiae	5.5	[153]
	serum albumin	Human	Kluyveromyces lactis	1.05	[154]
	serum albumin	Human	K. phaffii	8.86	[155]
	serum albumin	Human	K. phaffii	10.0	[156]
	serum albumin	Human	K. phaffii	11.0	[157]
	serum albumin	Human	K. phaffii	17.47	[158]

* These proteins are human-like collagen consisting of the triple-helix repeat structure of collagen. ** No information is available if these proteins are hydroxylated. *** Mutant forms of the proteins. **** Protein fused to a single chain antibody.

).

The bovine κ-CN has also been reported to be expressed in E. coli, but without production data. Kim and collaborators [125] explored the expression of bioactive peptides derived from caseins, managing to express the human κ-CN macropeptide (MP-κ-CN) extracellularly in S. cerevisiae and K. phaffii, with higher production observed in S. cerevisiae (Table 2). Despite the advances that the production of recombinant caseins can bring, enabling the production of lines of non-allergenic dairy products, to date, no company is reportedly producing the human caseins. On the other hand, several companies (

Table 3. Examples of companies producing recombinant animal proteins by precision fermentation (source: https://gfi.org/resource/alternative-protein-company-database/, and https://proteindirectory.com/, both accessed on 15 March 2024).

Company	Protein	Products	Host Microrganism	Source	Website
All G Foods (Sydney, Australia)	Milk proteins	Dairy		Bovine	https://www.allgfoods.com/ (accessed on 3 May 2024)
Ark Bio Solutions (Florianópolis, Brazil)	Lactoferrin	Foods and supplements	K. phaffii	Human	https://arkbio.com.br/ (accessed on 3 May 2024)
Better Dairy (London, Great Britain)	Caseins	Dairy		Bovine	https://betterdairy.com (accessed on 3 May 2024)
Change Foods (San Francisco, CA, USA)	Caseins	Dairy		Bovine	https://www.changefoods.com/ (accessed on 3 May 2024)
De Novo Foodlabs (Durham, NC, USA)	Lactoferrin	Dairy and supplements		Human	https://denovofoodlabs.com/ (accessed on 3 May 2024)
Eden Brew (Sydney, Australia)	Caseins	Dairy		Bovine	https://www.edenbrew.com.au (accessed on 3 May 2024)
Eggmented Reality (Kiryat, Israel)	Ovalbumin	Egg white for foods		Chicken	https://eggmented.com/ (accessed on 3 May 2024)
Evonik (Essen, Germany)	Collagen-like	Pharmaceutical cell culture and tissue	E. coli K. phaffii		https://corporate.evonik.com/ (accessed on 3 May 2024)
Fibrogen (San Francisco, CA, USA)	Collagen	Medicines		Human	https://www.fibrogen.com/ (accessed on 3 May 2024)
Geltor (Emeryville, CA, USA)	Collagen, elastin-like	Cosmetics	E. coli	Jellyfish Sponge Human	https://geltor.com/ (accessed on 3 May 2024)
Harmony (Boston, MA, USA)	Milk proteins	Infant formulas		Human	https://harmonybabynutrition.com/ (accessed on 3 May 2024)
Helaina (New York, NY, USA)	Lactoferrin	Infant formulas	K. phaffii	Human	https://www.myhelaina.com/ (accessed on 3 May 2024)
Imagindairy (Haifa, Israel)	β-Lactoglobulin	Dairy	A. oryzae	Bovine	https://imagindairy.com/about/ (accessed on 3 May 2024)
Imposible™ Foods (Redwood City, CA, USA)	Leghemoglobin		K. phaffii	Soy	https://impossiblefoods.com (accessed on 3 May 2024)
Jellatech (Raleigh, NC, USA)	Collagen, Gelatin	Cosmetics and foods		Human	https://www.jellatech.com/ (accessed on 3 May 2024)
Modern Meadow (Nutley, NJ, USA)	Collagen III	Biomaterials	K. phaffii	Human	https://modernmeadow.com/ (accessed on 3 May 2024)
Motif FoodWorks (Boston, MA, USA)	Myoglobin	Plant-based meat	K. phaffii	Bovine	https://madewithmotif.com/ (accessed on 3 May 2024)
New Culture (San Francisco, CA, USA)	Casein	Mozzarella	K. phaffii	Bovine	https://www.newculturefood.com/ (accessed on 3 May 2024)
Onego. Bio (Helsinki, Finland)	Ovalbumin	Egg white for foods	T. reesei	Chicken	https://www.onego.bio/ (accessed on 3 May 2024)
Otro (Marousi, Belgium)	Ovalbumin	Egg white for foods		Chicken	https://www.otrofoods.com/ (accessed on 3 May 2024)
Perfect Day (Berkeley, CA, USA)	β-Lactoglobulin α-Lactalbumin	Dairy	T. reesei	Bovine	http://www.perfectdayfoods.com/ (accessed on 3 May 2024)
ReMilk (Rehovot, Israel)	β-Lactoglobulin	Dairy	K. phaffii	Bovine	https://www.remilk.com (accessed on 3 May 2024)
Sartorius (Göttingen, Germany)	albumin Recombumin®	Reagents for laboratories	S. cerevisiae	Human	https://www.sartorius.com/en (accessed on 3 May 2024)
The Every Company (Daly City, CA, USA)	Ovomucoid	Drinks, food supplements	K. phaffii	Chicken	https://theeverycompany.com/ (accessed on 3 May 2024)
TurtleTree (Singapore)	Lactoferrin	Foods and supplements		Human	https://www.turtletree.com/ (accessed on 3 May 2024)
Up Dairy (São Paulo, Brazil)	β-Lactoglobulin	Dairy	T. reesei	Bovine	https://updairy.co/ (accessed on 3 May 2024)

), such as New Culture (San Francisco, CA, USA), have stood out in the production of bovine β-casein through precision fermentation, aiming to create animal-free cheeses. They have managed to produce mozzarella with the same texture, flavor, and melting profile as conventional animal-based mozzarella, and are already expanding their fermentation process to industrial manufacturing volumes [159].

Regarding whey proteins, there are also several old manuscripts describing the expression of α-lactalbumin (from humans, goats, and bovines) in different microorganisms (E. coli, S. cerevisiae, and K. phaffii), but without production data, or reported quantities below 1 mg/L. The best results were obtained with human α-lactalbumin (the most abundant whey protein in human milk) expressed with an α-factor secretory signal peptide, coexpressing a human disulfide isomerase and the AOX1 promoter in K. phaffii (Table 2). Thanks to their high protein quality, characterized by high digestibility, richness in amino acids, neutral flavor profile, and excellent water solubility, α-lactalbumin preparations are suitable for a variety of food applications, including beverages and infant formulas [100,160]. β-Lactoglobulin has attracted the attention of numerous precision fermentation companies, due to its soluble and emulsifying properties, fundamental for gelation in protein concentrates, in addition to its nutritional properties [101]. The best results reported are with the bovine protein expressed in K. phaffii and Trichoderma reesei (Table 2). In both contexts, the functional properties of recombinant β-lactoglobulin, such as emulsion-forming capacity, solubility, interface adsorption behavior, and emulsifying properties, have been investigated and shown to be similar to those of β-lactoglobulin of animal origin [127,129]. Due to α-lactalbumin being the second most abundant type of whey in bovine milk (Table 1), companies such as Perfect Day (Berkeley, CA, USA), and probably others, are also exploring the recombinant production of this protein (Table 3). Bovine β-lactoglobulin has also been the target of production by several companies, contributing to the development of milk-analogous products and dairy alternatives without animal derivatives, such as ice cream, cream cheese, and protein powder supplements (Table 3).

In the case of lactoferrin, the demand for this protein, driven by its applications in infant nutrition, immunological health, sports nutrition, cosmetics, and maternal and neonatal nutrition [161,162,163,164], has caused the market to project an annual growth for this protein of between 10% and 12% in the coming years [165]. However, lactoferrin is found in very low concentrations in bovine milk (Table 1), its main source being cheese whey, skimmed milk and their by-products, resulting in low lactoferrin production and limiting its availability, which makes this product expensive and scarce, found only in high-value niches such as supplements [166]. This scarcity, combined with the various health benefits attributed to it, motivated research that successfully demonstrated its recombinant expression in E. coli, but as is the case with the proteins described above, with very low yields. Using the AOX1 promoter in K. phaffii allowed the achievement of a significant production, with a yield of up to 3.5 g/L of recombinant bovine lactoferrin (Table 2). Some studies have already highlighted the potential of precision fermentation in the production of human lactoferrin, as illustrated in Table 2. Using K. phaffii and the AOX1 promoter, human lactoferrin reached a production of 1.2 g/L [103], while the use of filamentous fungi such as A. awamori allowed a remarkable yield of 2 g/L, the highest recorded in the scientific literature to date [130].

On the other hand, replication of the human glycosylation pattern on lactoferrin represents a significant challenge, considering the crucial role of post-translational modifications of this protein in its antimicrobial activity. Glycoproteins produced from mammalian cells invariably exhibit N-glycan heterogeneity, resulting in a mixture of glycoforms that varies from production batch to production batch. However, the extent and type of N-glycosylation have a profound impact on the therapeutic properties of many proteins [167,168,169]. Studies have successfully demonstrated a glycoengineering strategy in K. phaffii that enables the production of completely humanized and immunologically compatible recombinant lactoferrin, although with considerably lower yields (Table 2) [133,170]. It is well established that glycosylation of human lactoferrin occurs predominantly at three sites: Asn-156, Asn-497, and Asn-642 [167]. The process to produce humanized lactoferrin involves eliminating endogenous yeast glycosylation pathways, such as some glycosyltransferases, followed by the gradual introduction of heterologous glycosylation enzymes, including mannosidases, other glycosyltransferases, and epimerases [168,170]. This approach contributes to increasing the half-life of the glycoprotein in vivo and eliminates allergenic potential, thus enhancing the therapeutic value of yeast-derived glycoproteins [171]. The discrepancy between supply and demand creates a challenge in the widespread use of lactoferrin due to the lack of a stable and high-yield supply chain [166]. To overcome this obstacle, several companies have explored the production of human lactoferrin through precision fermentation (Table 3), aiming to not only solve the shortage problem but also ensure quality and functionality that meets human needs. Companies such as Turtle Tree (Singapore) and De Novo (Durham, NC, USA) emerged with the aim of widespread use of this protein in various market niches, while companies such as Helaina (New York, NY, USA) and Harmony (Boston, MA, USA) are focused on creating infant formula that is more suitable for newborns.

5.2. Egg-White Proteins

Eggs represent one of the most universal foods, widely consumed around the world. They are recognized as a primary source of protein in the global diet, transcending religious and ethnic barriers. The largest component of eggs, the egg-white, is valued in the food industry due to its high bioavailability, richness in essential amino acids and functional versatility. This versatility includes properties such as gelling, foaming, and emulsification [172,173,174]. Its composition is predominantly ovalbumin (54%), followed by ovotransferrin (12%), ovomucoid (11%), and with smaller amounts of ovomucin (3.5%), lysozyme (3.5%), and traces of other proteins including, for example, avidin (0.05%). These proteins offer a range of beneficial biological activities [175,176,177]. For example, lysozyme, characterized by its slightly sweet taste, has an effective antimicrobial action and is used as a food preservative, helping to prevent the proliferation of pathogenic bacteria in the production of meat products [178]. Ovotransferrin is applied both as a metal transport agent, as well as an antimicrobial and anticancer agent. Additionally, ovomucin and ovomucoid have been studied for their tumor suppressive properties, enhancing their use as anticancer agents [173,179].

Efforts to recombinantly express the proteins present in egg white, in particular chicken ovolabumin (in E. coli, S. cerevisiae, or K. phaffii) have been carried out since the 1970s, but without concrete data on productivity, or with extremely low production levels (few mg/L). However, Yang and colleagues achieved an impressive production of 5.45 g/L of quail ovalbumin using K. phaffii [135] (Table 2). Chicken ovotransferrin, the second most abundant protein in egg white, was also expressed using this yeast, with yields of approximately 0.1 g/L (Table 2). Smaller proteins, such as lysozyme and avidin, have also been successfully expressed using K. phaffii, with yields of 0.4 g/L and 0.33 g/L, respectively [132,138].

Recently, the high environmental impact associated with poultry farming [34] and concerns related to animal welfare have driven interest in the development of egg proteins through precision fermentation for the food sector. This technological advancement has been gaining global attention, with several companies emerging worldwide dedicated to this purpose (see Table 3). Among these innovations, the company The Every (Daly City, CA, USA, previously known as Clara Foods Co.) stands out as a pioneer in the production of proteins derived from egg whites with the aim of offering alternatives to those of animal origin, paving the way for the many others that came after. With a recombinant egg white production system, The Every has introduced products to the market that incorporate recombinant ovomucoids, already available for specific culinary applications such as baking and beverages, although for now they are limited to the United States market. These recombinant egg whites reportedly have the same baking and cooking functionality as their animal counterparts, offering a sustainable and ethical alternative for food production.

5.3. Structural Proteins

Collagen is the most abundant structural protein in animal body, representing approximately 30% of the total protein [180]. It is widely distributed in the extracellular matrix, exhibiting an important biological role in tissue formation, organ support, body protection, tissue damage repair, and signaling [181]. Due to its physical properties, collagen is used in several industries [182]. In the food industry, it serves as an emulsifier, film-forming material, gelling agent, stabilizer, and a source of proteins and peptides [183]. Its mechanical strength, biodegradability, and ability to form fibrils make it ideal for biomedical applications, including tissue engineering scaffolds and drug delivery systems [184,185]. In addition, in cosmetic formulations, collagen or derivative proteins have been employed as a natural ingredient, moisturizer, and anti-aging agent [186,187].

Collagens are classified into 28 distinct types based on protein and/or DNA sequence information, having different functions and features. The collagen molecule consists of a triple helix structure formed by three polypeptides (called α-chains, but there are not α-helixes) that can be identical (homotrimeric collagen) or different (heterotrimeric collagen), containing varying lengths of the three amino acid repeat glycine-X–Y, where X and Y are any amino acid but commonly proline and hydroxyproline, respectively [180,181,182]. The structure and function of collagen are significantly impacted by the amino acid sequence and post-translational modifications, which include the hydroxylation of specific lysine and proline residues, as well as the proteolytic cleavage of the N- and C-terminal of the soluble precursor procollagen to generate the mature collagen molecules that, then, self-assemble into fibrils or networks in the extracellular matrix [180,182].

Currently, collagens come mostly from animal sources, such as bovine hides and porcine and fish tissues. Increasing concerns about their biocompatibility, the potential to cause immunogenic reactions or transmit pathogenic vectors, and lack of product homogeneity, have driven the development of new methods for collagen manufacture from non-animal sources [181,182,183,184,185,186,187,188]. Thus, the expression of recombinant collagens using different prokaryotic and eukaryotic systems is an alternative strategy to address these aforementioned issues, and there have been many publications regarding the production of recombinant collagen [189]. Despite mammalian cells and plants having also been employed as producing organisms (reviewed in [184,190]), here, we will focus on microbial production of these proteins. Production of recombinant human-like collagens or derivative proteins were achieved in engineered E. coli and K. phaffii, with protein concentrations varying from 1 to more than 10 g/L (Table 2). Collagen production through fermentation usually involves two steps, starting with a batch phase fermentation used to reach high cell densities, followed by a fed-batch phase to increase the protein expression [140,141,184]. However, in general, the proteins produced have shorter polypeptide sequences and lack post-translational modifications, differing from human proteins in terms of structure, stability, and overall properties. Furthermore, the co-expression of hydroxylases was used to produce the proline and lysin hydroxylated versions of collagen, although with significantly lower (or no data reported) protein production [191,192,193,194]. Despite the scientific efforts, only in recent years have biotechnological companies such as Geltor (Emeryville, CA, USA), Modern Meadow (Nutley, NJ, USA), Jellatech (Raleigh, NC, USA), and Evonik (Essen, Germany) made significant progress in producing recombinant collagen through precision fermentation at large scale (Table 3). Their portfolios account for several products developed to achieve the commercialization of collagen proteins or derivatives for application in pharmaceutical, medical, food, and textile industries.

Elastin is a structural protein polymer of the extracellular matrix that is crucial to maintaining the elasticity of vertebrate connective tissues, and tropoelastin is the soluble precursor of elastin. In order to form elastin, tropoelastin monomers assemble into a stable polymer structure by lysine-mediated crosslinking (forming desmosine) catalyzed mainly by the enzyme lysyl oxidase in a complex multi-step process involved in the elastic fibers’ formation. Crosslinking results in the insoluble and resistant mature protein, being essential for the structural integrity and function of elastin [195]. Unlike collagen, tropoelastin is encoded by a single gene that when expressed is spliced to produce different isoforms of tropoelastin proteins to meet the functional requirements in the different tissues. This gene has been expressed in E. coli, S. cerevisiae, and K. phaffii systems, nonetheless, protein expression can be challenging due to the highly repetitive gene sequence of tropoelastin that is prone to mutational events, lack of protein secretion, and also reduced levels of protein expression [196,197]. To address this issue, attempts have been made to express elastin-like proteins (Table 2) using synthetic designed nonrepetitive DNA sequences and/or peptide repeats. These approaches have led to the creation of a diversified range of elastic polymers with specific characteristics and properties [145,198,199,200] that can be exploited to develop functional and biocompatible materials, with thermoresponsive properties, for application in tissue engineering, drug delivery, and cosmetic formulations. However, apparently there is no company producing tropoelastin or synthetic elastin-like proteins.

5.4. Flavoring Proteins

Hemoproteins are a class of proteins that contain a heme prosthetic group, which is a complex of iron and a large organic molecule called porphyrin. The most well-known example of a heme protein is hemoglobin, which is responsible for transporting oxygen in the blood of vertebrates, the adjustment of intracellular pH, as well as modulator of erythrocyte metabolism [201]. In addition to hemoglobin, myoglobin (Figure 3) is also a protein conjugated to a heme prosthetic group, allowing tissues to accumulate oxygen, especially in animal muscles [202,203]. Overall, hemoproteins play diverse and essential roles in biological processes, ranging from oxygen transport, scavenging for nitric oxide and reactive oxygen species, to energy production and cellular regulation [203,204]. The hemoglobins and myoglobins have a wide versatility of application since they have been studied and used in the areas of medicine and food. Hemoglobins have been adopted as acellular oxygen transporters, iron supplying agents, and coloring and flavoring agents in the food industry. The use of recombinant human hemoglobin as an oxygen carrier in the production of artificial blood, for example, has been an alternative explored to meet the demand for blood transfusions worldwide [205,206,207].

Myoglobin is an important contributor to the sensory quality of meat, related to the red tone and metallic flavor. Furthermore, vegetable hemoglobin derived from soy, called leghemoglobin, is approved for use in plant-based meat, providing more authenticity in color and taste [208,209,210]. In the food industry, heme proteins play the role of intensifying the color, smell, and flavor of meat products. As aforementioned, according to The Food and Agriculture Organization, by 2050 the demand for meat is likely to increase by up to 70%, which becomes a major concern due to the environmental problems caused by industrial agriculture [18]. Therefore, the search for technologies to develop products analogous to animal meat is a promising alternative, but it still faces a major challenge in being able to imitate the texture, appearance, and taste of animal meat [211,212]. In this sense, taking into account the relevance that these organoleptic characteristics have in consumer acceptance, the addition of heme proteins to plant-based meat has great potential in recreating products analogous to animal meat.

In the case of hemoglobin, the challenge is to balance the expression of the two different globin subunits (the α and β polypeptides), as well as the supply of the prosthetic heme required for obtaining the active hemoglobin. In E. coli, the efficient production of human hemoglobin was achieved through the expression of a heterologous heme transport system (Table 2), although other approaches (through different combinations of heme synthesis genes) are promising [213], but lacking detailed production data. The expression and production of hemoglobin in yeasts (K. phaffii and S. cerevisiae) also have these challenges, and lower yields have been obtained [147,214,215], although significant improvements have been reported showing the production of 18% of intracellular hemoglobin relative to the total yeast protein [216]. Myoglobin has also been produced by E. coli on a gram scale [217], and in the case of yeast platforms the best results were obtained with K. phaffii (Table 2) by improving heme biosynthesis and inhibiting heme degradation [147], or improving the fermentation conditions of appropriate genetically modified yeast strains [148]. Although soy leghemoglobin is certainly not an animal protein, we also included it in Table 2 due to the efficient production of this protein by the yeasts K. phaffii and K. marxianus. This protein has been approved by the Food and Drug Administration (FDA, USA) agency for use in plant-based meats, improving the authenticity of the color and flavor of these products [209,210,211,212]. Notably, soy hemoglobin and bovine myoglobin synthesized by K. phaffii are used by Impossible Foods Inc. (Redwood City, CA, USA) and Motif FoodWorks Inc. (Boston, MA, USA) to develop meat analogous products like Impossible Burgers and HEMAMI, respectively (Table 3).

5.5. Other Proteins

Nowadays thousands of recombinant proteins (industrial enzymes, insulin, various hormones, antibodies, therapeutic proteins, etc.) are produced by microorganisms through precision fermentation, and a description of all these approaches is certainly beyond the objectives of this review. To finalize, we would like to show results obtained with the production of another abundant animal protein, serum albumin (Figure 3). Human serum albumin constitutes about half of the blood serum proteins and is present at a concentration of 35–40 g/L of blood. Albumin maintains the osmolarity of the bloodstream (homeostasis), serves as an essential source of reserve protein during starvation, and is also a carrier for hormones, fatty acids, vitamins, bilirubin, and several divalent metal ions. It affects the pharmacokinetics of many drugs, providing the metabolic modification of some ligands (rendering potential toxins harmless), and accounts for most of the anti-oxidant capacity of human plasma [218,219]. It has wide usage as a therapeutic for restoration of blood volume during accident, trauma, and burn injury, and as a carrier of drugs for life-threatening diseases such as cancer, cardiovascular problems, diabetes, and inflammation [218,219].

There is a large demand for this protein, which is currently sourced from human plasma, carrying the risk of contamination with viruses. Thus, and since it is a non-glycosylated protein, functional human serum albumin has been produced through recombinant technologies using bacteria, yeasts, and animal and plant cells [220]. While the expression in E. coli and S. cerevisiae is very low, requiring mutant forms of albumin, the fusion with other proteins was successfully employed with this yeast (Table 2). The best results have been obtained with K. phaffii, not only using appropriated promoters (AOX1 or a mutated AOX2 promoter) and specific yeast strains, but also medium and pH optimization, optimal methanol-feeding and oxigen-feeding policy, and fermentation process using high cell densities. These precision fermentation approaches allowed the production of more than 17 g/L albumin, the highest yield of a recombinant animal protein ever reported (Table 2). Finally, it should be noted that recombinant albumin has the same biological properties as the one obtained from human serum [221,222,223,224]. There is already in the market a recombinant human serum albumin (Recombumin^®) made with S. cerevisiae (Table 3) and commercialized by Sartorius (Göttingen, Germany) [225].

6. Precision Fermentation in the World—The State of Industry

As a consequence of anticipated population growth, the Food and Agriculture Organization (FAO) of the United Nations projects that the consumption of meat and dairy products will increase by 102% and 82%, respectively, by 2050 [226]. These needs, along with the growing consumer demand for sustainable, environmentally friendly, cruelty-free products, and the pressure to meet the goals of the Paris Agreement [6,14], as well as the increasing government support in this area worldwide [15,227,228,229,230,231], are some of the factors driving the development and expansion of the global alternative protein market.

In this context, precision fermentation is gaining increasing attention, proposing a future where foods have similar taste, texture, aroma, appearance, and nutritional quality as animal-derived products, but are produced without the ethical and environmental costs associated with traditional livestock farming. Good examples of such products include Perfect Day’s (Berkeley, CA, USA) milk proteins, Every’s (Daly City, CA, USA) egg white, and flavor proteins like Motif FoodWorks’ (Boston, MA, USA) myoglobin (Table 3). These proteins are being used to produce milk and its derivatives, sweets and nutritious drinks, and flavorings for plant-based meats, respectively. However, the benefits go far beyond food production. Proteins such as collagens, widely used in the cosmetic, medical, and food industries, are also being produced by precision fermentation. Geltor (Emeryville, CA, USA), for example, is producing human collagen already marketed for use in cosmetics. Additionally, Modern Meadow (Nutley, NJ, USA) is producing collagen for the manufacture of biomaterials that replace animal leather. Other examples of companies and products derived from precision fermentation can be found in Table 3.

The global precision fermentation market was valued at USD 1.6 billion in 2022 and is expected to reach around USD 67.9 billion by 2032, growing at a compound annual growth rate of 46% during the forecast period from 2023 to 2032 [232]. In a period of just 10 years (2013 to 2022), dozens of new companies emerged in this sector. Together, these companies have already raised a total of an impressive USD 1.946 billion [233]. Despite the precision fermentation industry still being in its early stages, it has already attracted the interest of major food conglomerates, including Nestlé (Vevey, Switzerland), Unilever (London, Great Britain), AB InBev (New York, NY, USA) and General Mills (Minneapolis, MN, USA), through partnerships and new product launches [233], serving as de-risking events for investors who are increasingly attentive to the category. Although the past few years have been marked by a slowdown in the global economy due to pandemics and wars, the status of alternative proteins as an increasingly important environmental, social, and governance opportunity provides potential advantages for investors and the industry [234,235,236]. Recently, the company New Culture (San Francisco, CA, USA) announced a commercial partnership with the South Korean biotech giant CJ CheilJedang (Seoul, Republic of Korea), allowing access to larger facilities and unlocking competitive prices for casein derived from precision fermentation. This collaboration exemplifies how to increase production and reduce the costs of products from this type of technology [237].

By producing bioidentical proteins to those found in animals, precision fermentation offers application opportunities in both the cultivated meat and plant-based industries, with the latter responsible for about 58% of applications [123,232,238]. Additionally, precision fermentation also offers the possibility of producing as yet non-existing products, such as those produced with bioidentical human proteins, for the production of non-allergenic and more suitable nutritional product lines, especially for infants [126,132]. Although it is a new market, it is expected that the popularity of precision fermentation will grow as consumers seek more sustainable and ethical alternatives to conventional animal products [239]. A recently conducted survey [240] pointed to acceptance and enthusiasm for new technologies such as precision fermentation, particularly among younger consumers. A significant 40% of adults also show interest in trying precision fermentation-based technologies. The survey also reveals a notable willingness to adapt lifestyles in favor of more sustainable practices, with more than half of respondents open to drastic changes to improve environmental impacts. Notably, a large majority (77%) of consumers express willingness to try precision fermentation-derived products once they understand their benefits, highlighting a strong market potential for this type of innovation in the food industry [240].

7. Conclusions

Growing consumer demand for sustainable, environmentally friendly, and cruelty-free products, as well as increasing government support in this area around the world, are some of the factors that have stimulated the development and expansion of the alternative protein market globally. Precision fermentation represents a groundbreaking approach for modern industries, particularly in the food and pharmaceutical sectors. While it holds immense promise for revolutionizing various fields, it also confronts several challenges and offers intriguing future prospects in the modern world. One of the foremost challenges facing precision fermentation is the scale-up process. While laboratory-scale production showcases feasibility, transitioning to commercial-scale operations remains a hurdle. Achieving cost-effective mass production without compromising quality demands innovative engineering solutions and optimization of fermentation processes. Moreover, regulatory frameworks lag behind the rapid advancements in precision fermentation. Establishing comprehensive guidelines to ensure product safety, efficacy, and labeling transparency is crucial. Addressing ethical concerns, particularly regarding genetically modified organisms (GMOs), necessitates nuanced dialogue and regulatory updates.

Despite these challenges, precision fermentation presents promising future prospects. In the food industry, it offers sustainable alternatives to traditional animal agriculture, mitigating environmental degradation and resource depletion. Cultivating meat, dairy, and other animal proteins through fermentation reduces land and water usage while minimizing greenhouse gas emissions. Furthermore, precision fermentation holds immense potential in personalized medicine and healthcare. Tailoring therapeutic proteins and pharmaceuticals to individual genetic profiles could revolutionize treatment efficacy and patient outcomes. Additionally, it enables the production of rare or complex molecules that are challenging to obtain through conventional methods, fostering innovation in drug development. In this context, while precision fermentation encounters obstacles in scalability and regulatory frameworks, its transformative potential in various industries is undeniable. As research and innovation propel this technology forward, it holds promise for addressing global challenges and shaping a more sustainable and prosperous future.